Straits Times Index
3,287.38 -0.37 (-0.01%) Nikkei
37,682.78 +54.30 (+0.14%) Hang Seng
17,336.20 +51.66 (+0.30%) FTSE 100
8,078.86 +38.48 (+0.48%) Bitcoin USD
64,240.47 -217.95 (-0.34%) CMC Crypto 200
1,381.74 -0.83 (-0.06%)
CStone Pharmaceuticals (2616.HK)
| Previous close | 0.920 |
| Open | 0.910 |
| Bid | 0.850 x 0 |
| Ask | 0.950 x 0 |
| Day's range | 0.900 - 0.930 |
| 52-week range | 0.800 - 3.400 |
| Volume | |
| Avg. volume | 2,563,908 |
| Market cap | 1.148B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2023 annual results and recent business updates.
- PR Newswire
CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the National Medical Products Administration (NMPA) of China has approved the supplemental biologics license application (sBLA) for sugemalimab (Cejemly®) in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment for unresectabl
- PR Newswire
CStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Servier, a global independent pharmaceutical group, today announced an agreement whereby Servier acquires from CStone the exclusive rights to develop and commercialize TIBSOVO® (ivosidenib tablets) in Greater China and Singapore.
